CTMX

Rating neutralAI Memo

CytomX Therapeutics

As of 2026-10-14/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-14 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Varseta-M colorectal-cancer data and dose selection • 2026-12-31

Base target: $3 / p=45% prob

Biggest risk

The valuation remains concentrated in unproven clinical programs. Q2 revenue fell to $1.4 million from $18.7 million a year earlier as collaboration activity declined, while R&D expense rose to $17.6 million from $13.3 million, primarily reflecting Varseta-M manufacturing and personnel costs [#SEC-8K-2026-08-06]. Disappointing efficacy, tolerability, or trial-design alignment could overwhelm the runway advantage.

Invalidation

Break below $1 or thesis failure.

What would change my mind?

The year-end Varseta-M update could support dose selection and the planned registrational study. CytomX also announced FDA Fast Track designation for Varseta-M in relapsed/refractory metastatic colorectal cancer; the designation is not approval [#IR-2026-08-27] (https://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-announces-fda-fast-track-designation). The Q2 release reported $330.3 million of cash and investments at June 30, a subsequent $37 million Regeneron payment, and an expected runway to at least the second half of 2028 [#SEC-8K-2026-08-06].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-14

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Second-line colorectal-cancer combination trial start
CX-801 melanoma combination data
Registrational-study alignment and initiation

BearKey bullets

FDA alignment, treatment-line choice, comparator, and timing of the planned registrational study remain uncertain [#SEC-8K-2026-08-06].
Fast Track designation does not guarantee accelerated development, approval, or commercial uptake.
Rising development spending and lower collaboration revenue could shorten the projected runway if costs or trial scope exceed plan [#SEC-8K-2026-08-06].

WatchKey bullets

Varseta-M colorectal-cancer data and dose selection

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $3 (p=45%)

Target spread vs base: +46% / -54%

Scenario probabilities

Bull Target: $4 (p=25%)Base Target: $3 (p=45%)Bear Target: $1 (p=30%)

Commentary

The deterministic prior is positive and the primary-source milestone calendar is substantive, but this remains a low-coverage, binary clinical monitoring case. The supplied news is chiefly from August; a dependable post-release price attribution, analyst revisions, options skew, short interest, employee sentiment, and sufficient social coverage are unavailable. Zero sentiment fields denote unavailable readings, not neutral measurements.

As of 2026-10-14 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Second-line colorectal-cancer combination trial start
CX-801 melanoma combination data
Registrational-study alignment and initiation

Scenarios

Bull Target (Scenario probability)

$4 / p=25% prob

Base Target (Scenario probability)

$3 / p=45% prob

Bear Target (Scenario probability)

$1 / p=30% prob

Analysis 2026-10-14 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Varseta-M colorectal-cancer data and dose selection
CytomX expects a Phase 1 update by year-end 2026 after enrolling 113 patients. Efficacy durability and safety at the selected dose are the central tests of the planned registrational path [#SEC-8K-2026-08-06].
Prob 85.00% • Move 25.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

Second-line colorectal-cancer combination trial start
2026-12-31
The company plans to start a Phase 1/2 study combining Varseta-M with bevacizumab, 5-fluorouracil, and leucovorin in Q4 2026. Starting the study would advance the earlier-line strategy, but would not establish efficacy [#SEC-8K-2026-08-06].
Prob 80% • Move 8% • Priced-in 50%

Long-term Catalysts

Months to a year

CX-801 melanoma combination data
2027-06-30
Initial Phase 1 data for CX-801 with pembrolizumab in advanced melanoma are expected in the first half of 2027. This is a distinct, early-stage pipeline test rather than a near-term commercial driver [#SEC-8K-2026-08-06].
Prob 65% • Move 10% • Priced-in 25%
Registrational-study alignment and initiation
2027-06-30
CytomX plans FDA interactions and aims to initiate a Varseta-M monotherapy registrational study in the first half of 2027. Final design remains contingent on maturing clinical data [#SEC-8K-2026-08-06].
Prob 60% • Move 20% • Priced-in 35%

Risks

FDA alignment, treatment-line choice, comparator, and timing of the planned registrational study remain uncertain [#SEC-8K-2026-08-06].
Fast Track designation does not guarantee accelerated development, approval, or commercial uptake.
Rising development spending and lower collaboration revenue could shorten the projected runway if costs or trial scope exceed plan [#SEC-8K-2026-08-06].
Varseta-M efficacy and safety at the eventual registrational dose remain unproven; early Phase 1 findings may not predict later results [#SEC-8K-2026-08-06].

Peers

Symbol	Summary
AMGN	A much larger commercial biotechnology company and CytomX collaboration counterparty, not a suitable direct valuation peer.
ACRS	Similar market capitalization and clinical-stage biotechnology exposure, but not a direct Varseta-M program or indication peer; a weak valuation comparator.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-14

Loading AI feed…

Symbol

Summary

AMGN

A much larger commercial biotechnology company and CytomX collaboration counterparty, not a suitable direct valuation peer.

ACRS

Similar market capitalization and clinical-stage biotechnology exposure, but not a direct Varseta-M program or indication peer; a weak valuation comparator.